In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Vigorous physical activity may preserve cognitive function in high-risk HTN
Jun 24, 2024
High versus low vigorous physical activity was linked to a lower risk of mild cognitive impairment, probable dementia and MCI/probable dementia in a multivariate model.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
The 5-Cog paradigm improves diagnosis, management of dementia
Jun 11, 2024
A threefold improvement was seen in dementia care actions with the 5-Cog paradigm, a culturally adept cognitive detection tool.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...